U.S. Markets closed

Cell Therapeutics raises $14.8M in convertible preferred stock sale

Cell Therapeutics announced that it has agreed to sell 15,000 shares of its Series 18 Preferred Stock directly to Quogue Capital LLC and an affiliate of Perceptive Advisors LLC in a registered direct offering conducted without an underwriter or placement agent.